Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo
If a protective effect of statins on breast cancer recurrence is supported by evidence from the MASTER trial, then the indications for a safe, well-tolerated, and inexpensive treatment can be expanded towards improved clinical outcomes for breast cancer patients.
Authors
- Signe Borgquist (ORCID: https://orcid.org/0000-0001-7938-8893)
- Marianne Ewertz (ORCID: https://orcid.org/0000-0002-5965-969X)
- Maj‐Britt Jensen (ORCID: https://orcid.org/0000-0001-5348-3040)
- Bent Ejlertsen (ORCID: https://orcid.org/0000-0001-8761-714X)
- Birgitte Vrou Offersen (ORCID: https://orcid.org/0000-0001-7356-2096)
- Peer Christiansen (ORCID: https://orcid.org/0000-0003-2748-9240)
- Anders Bonde Jensen (ORCID: https://orcid.org/0000-0002-6319-563X)
- Deirdre Cronin‐Fenton (ORCID: https://orcid.org/0000-0001-9738-2284)
- Annette Raskov Kodahl (ORCID: https://orcid.org/0000-0003-0515-9144)
- Thomas P. Ahern (ORCID: https://orcid.org/0000-0003-0440-8727)
- Cecilie Linea Bendorff
Institutions
- University of Vermont (US)
- University of Southern Denmark (DK)
- Lund University (SE)
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Danish Breast Cancer Cooperative Group (DK)
Publication Details
- Journal
- Clinical Epidemiology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/clep.s509873
- Citations
- 6
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 5.62
Funders
- Novo Nordisk
- Novo Nordisk Fonden